
Naoyuki Nakada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5623225/publications.pdf Version: 2024-02-01



Νλογιικι Νλκλόλ

#	Article	IF	CITATIONS
1	Assessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites. Drug Metabolism and Pharmacokinetics, 2010, 25, 223-235.	2.2	52
2	Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metabolism and Pharmacokinetics, 2019, 34, 209-216.	2.2	46
3	Development of Murine <i>Cyp3a</i> Knockout Chimeric Mice with Humanized Liver. Drug Metabolism and Disposition, 2015, 43, 1208-1217.	3.3	26
4	Human mass balance, metabolite profile and identification of metabolic enzymes of [¹⁴ C]ASP015K, a novel oral janus kinase inhibitor. Xenobiotica, 2015, 45, 887-902.	1.1	21
5	Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans. Xenobiotica, 2015, 45, 757-765.	1.1	15
6	Murine <i>Cyp3a</i> knockout chimeric mice with humanized liver: prediction of the metabolic profile of nefazodone in humans. Biopharmaceutics and Drug Disposition, 2016, 37, 3-14.	1.9	14
7	Evaluation of the Utility of Chimeric Mice with Humanized Livers for the Characterization and Profiling of the Metabolites of a Selective Inhibitor (YM543) of the Sodium-Glucose Cotransporter 2. Pharmaceutical Research, 2017, 34, 874-886.	3.5	6
8	Cell tracking of chromium″abeled mesenchymal stem cells using laser ablation inductively coupled plasma imaging mass spectrometry. Rapid Communications in Mass Spectrometry, 2019, 33, 1565-1570.	1.5	4
9	Investigation of Metabolite Profile of YM758, a Novel If Channel Inhibitor. Drugs in R and D, 2016, 16, 205-216.	2.2	3
10	A phase I, open-label, single-dose micro tracer mass balance study of 14 C-labeled ASP7991 in healthy Japanese male subjects using accelerator mass spectrometry. Drug Metabolism and Pharmacokinetics, 2018, 33, 118-124.	2.2	3
11	Imaging Mass Spectrometry (IMS) for drug discovery and development survey: Results on methods, applications and regulatory compliance. Drug Metabolism and Pharmacokinetics, 2022, 43, 100438.	2.2	2